S-1 40mg/m2 is administered orally twice a day from day 1 to day 14 followed by a one-week rest.Paclitaxel 50mg/m2 is administered intravenously and paclitaxel 20mg/m2 is administered intraperitoneall
Sponsors
The University of Tokyo
Conditions
Advanced biliary tract cancer with carcinomatous ascitesAdvanced pancreatic cancer with carcinomatous ascites.
Phase 2
The efficacy and the safety of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced pancreatic cancer with carcinomatous ascites.
Active, not recruitingJPRN-UMIN000005306
Start: 2011-04-01Target: 30Updated: 2026-06-29
Feasibility study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced biliary tract cancer with carcinomatous ascites.
Active, not recruitingJPRN-UMIN000007520
Start: 2012-04-01Target: 30Updated: 2026-06-29